Nathan J Dowden has sold TRDA and made no open-market buys since Jun 2022

Nathan J. Dowden is President and Chief Operating Officer at Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company developing Endosomal Escape Vehicle (EEV™)-therapeutics for intracellular targets.( He joined Entrada in 2019 as Chief Operating Officer and was promoted to his current expanded role effective January 1, 2024, contributing to the company's growth to over 150 employees, advancement of the lead program ENTR-601-44 into the clinic, pipeline development, and establishment of new headquarters in Boston Seaport.(

Dowden brings over 30 years of strategy, investment, and operational experience in the healthcare sector. Prior roles include Senior Vice President of Strategy and Corporate Development at Rubius Therapeutics, where he supported evolution from early-stage discovery to clinical development; Managing Director roles at Huron Consulting Group and The Frankel Group LLC (16 years), advising on biopharma ventures, portfolio management, and commercialization; and positions at EY, Searle Pharmaceuticals, and CIGNA Healthcare. He holds an MBA from the University of Chicago Booth School of Business and a BS from the University of Connecticut.(

Written by Perplexity from public sources.